Role of Trichostatin A (TSA) in modulating the epigenetic modification in the lymphocytes of colorectal cancer (CRC) Authors: R. Ilaya Kumar, Kavya Jain, Harshnna Gururajan, Karan Raj Rai, Melvin George, Koustav Sarkar Published: 2025 ABSTRACT Trichostatin A (TSA) is a strong epigenetic tool that promises to have the future in the field of immune reprogramming, but its mechanisms of action in patient-derived immune cells in colorectal cancer (CRC) are still poorly studied. We examined in this current study the molecular and functional immune phenotype of lymphocytes of CRC patients and healthy donors in response to low-dose (0.1 nM), short-term (12 h) treatment with TSA, which aims at narrowing cytotoxicity and retaining epigenetic regulation. The TSA potentiated pro-inflammatory cytokines (IFN-gamma, IL-12, TNF-alpha) and inhibited immunoregulatory interleukins (IL-4, IL-10, IL-17, CCL5, Granzyme B in CRC-derived immune cells). At the transcriptional level, TSA induced TBX21 and TP53 and repressed GATA3, FOXP3, RORC, and MYC. Epigenetic profiling showed H3K14ac and H3K4me3 markups, H3K27me3 and HDAC1 downregulation, promoter hypermethylation of immune territory, less R-loop formation, and higher methylation of m6A RNA-partaking in the recommendation that TSA promotes chromatin and transcriptome multilayered modification. The TSA pretreated lymphocytes elicited cytotoxic effect in HT-29 CRC cells and also showed redox disproportion via depletion of glutathione and increase in nitric oxide. Although previous research focuses on the direct impact of TSA on tumor cells, in our study, we exclusively highlight TSA ability to reprogram the immune cells epigenetically in a more inflammatory tumor-reactive phenotype. The findings justify the possibility of TSA as an epigenetic adjunct of low toxicity in immuno-oncology and form a basis to continue in vivo and translational study in CRC immunotherapy. Introduction Colorectal cancer (CRC) is a leading global cause of cancer-related mortality, ranking among the top three most diagnosed malignancies and the second most common cause of cancer death worldwide [1]. CRC development is driven by a complex interplay of genetic and epigenetic alterations, including chromosomal instability, microsatellite instability, and widespread DNA methylation changes such as the CpG island methylator phenotype (CIMP). These epigenetic modifications can silence tumor suppressor and immune-regulatory genes, contributing to tumor progression and immune evasion. In this regard, CRC is the best model to investigate immune-epigenetic reprogramming as it has high rates of promoter hypermethylation, CIMP status, and a known lack of effectiveness in immune checkpoint inhibition [2]. The tumor microenvironment (TME) in CRC plays a crucial role in shaping disease progression and patient prognosis. A higher infiltration of Th1-type effector T cells has been associated with improved survival, whereas regulatory T cells (Tregs), immunosuppressive cytokines, and dysfunctional antigen presentation support immune tolerance and tumor persistence. Increasing evidence suggests that these immune imbalances are not purely stochastic but are regulated by epigenetic mechanisms such as histone modifications, DNA methylation, and RNA methylation, which influence T-cell differentiation, cytokine production, and immune responsiveness [2]. Histone deacetylase inhibitors (HDACi), such as Trichostatin A (TSA), can reverse transcriptional silencing by increasing histone acetylation, thereby reactivating genes involved in immune activation and tumor suppression. TSA has demonstrated the ability to modulate cytokine profiles, enhance tumor suppressor gene expression, and potentially remodel immune cell behavior [3]. Traditional cytotoxic treatment decreases the mass of a tumor; however, they do not prevent relapse. On the contrary, reprogramming of the immune system by TSA potentially provides lasting tumor control, at least in part due to its immune surveillance re-establishment [3]. There is proof of epigenetic memory being established even after relatively short-term HDAC inhibition, indicating that indeed TSA would be helping bring long-term effects which would not be cytotoxic in parallel [4]. However, most studies to date have focused on TSA’s direct cytotoxic effects on cancer cell lines, with limited understanding of its broader immuno-epigenetic impact, particularly in patient-derived immune cells. The specific molecular pathways through which TSA may reprogram immune responses in CRC remain underexplored. We tried to fill this gap by using peripheral blood lymphocytes (PBLs) of CRC patients rather than tumor or combination immune samples. PBLs have greater potential to maintain disease specific immune suppression and native epigenetic landscape necessary to study the systemic effects of TSA [5]. In this study, we investigate the short-term, low-dose effects of TSA on peripheral blood mononuclear cells (PBMCs) taken from CRC patients and healthy donors. We model with a 0.1 nM, 12-h in vitro exposure to characterize changes across the layers of the epigenome, the range of TSA-induced changes to histone acetylation, promoter DNA methylation, R-loop formation, and RNA m6A methylation, and the associated change in transcription factor expression, cytokine production, oxidative stress, and functional cytotoxicity. A pilot MTT assay (internal validation) was used to herald the test type of dose and time point that was called to recommend a dose of 0.1 nM TSA after 12 h as being able both to preserve cell viability but elicit sufficient molecular alterations to be measurable. We propose to combine these multi-dimensional analyses to understand whether TSA will be able to epigenetically reprogram the CRC lymphocyte toward a more pro-inflammatory anti-tumor phenotype [6]. Although our study is contained within acute in vitro lymphocyte studies, the results can offer mechanistic understanding of the immune-modulatory effect of TSA and can generate the scientific base to pursue the preclinical testing of HDAC inhibitors as adjuncts in the immunotherapy of CRC. Methods Blood sample collection and PBMC isolation All study procedures were undertaken with the help of guideline provided by the Institutional Ethics Committee at SRM Medical College Hospital and Research Centre, Kattankulathur, Tamil Nadu 603,203, India, and were accepted by the committees. Peripheral blood was collected from a colorectal cancer patient (Stage III; male; aged 28) prior to any treatment and a normal donor (male; aged 26). Samples were processed within 2 h of collection under standardized conditions to minimize variability. From CRC patients and healthy controls, 10 mL peripheral blood sample was obtained from EDTA tubes. PBMCs were isolated using Ficoll density centrifugation (mix blood 1:1 with PBS, overlay on Ficoll, centrifuged at 2200 rpm for 30 min). PBMCs were kept post resuspension at 1 × 106 cells/ml in culture medium for further assay procedures. Excess cells were preserved for further usage by placing them in freezing medium (10% DMSO in FBS) at –80°C [8] [9]. Preparation of Trichostatin A (TSA) solution A TSA stock solution was prepared using 99.99% pure TSA and sterile PBS at a concentration of 20 nM and aliquoted and stored at –20°C for stability. Prior to the experiments, working concentrations at 20, 10, 5, 2, 1, and 0.1 nM were established. After assessing cell viability by MTT assay (Pilot results), the low concentration and short treatment, i.e., 0.1 nM TSA and 12h, were chosen for treatments, to induce epigenetic changes, while maintaining cell viability [10]. Trichostatin A treatment of PBMCs PBMCs were seeded in 6-well plates at a density of 1 × 106 cells/mL in RPMI-1640 medium containing 10% FBS and antibiotic (penicillin streptomycin). Following treatment with 0.1 nM TSA (no treatment for control cells), the cells were allowed to incubate for 12 h at 37 °C in 5% CO2. The cells were twice washed with phosphate-buffered saline after the treatment. Using the cell pellets, the molecular assays were conducted, whereas the culture supernatants were stored at a − 80 °C to measure cytokines and nitrites [11]. Enzyme-linked immunosorbent assay (ELISA) ELISA was used to quantify IFNγ, IL-4, IL-10, IL-12, IL-17, TNFα, Granzyme B, and CCL5 cytokines in culture supernatants samples indirectly. They were tested with commercially available ELISA kits (OptEIA™ BD Pharmingen). After overnight incubation with antigen coated plates, the wells were incubated in 5% BSA for two hours to block them. Afterward, a blocking phase was followed by addition of primary antibodies specific for cytokines, appropriately diluted, and incubated, and posteriorly washed with 5% BSA repeated times. Then, wells were later incubated again after addition of HRP-conjugated secondary antibodies. To start the development of color, substrate TMB was used; afterward followed by a suitable acidic stop with 1N sulfuric acid. Absorbance was read at 450 nm. Cytokines’ amounts in the samples were determined by comparing them with standard curves obtained using varying amounts of antigen [12]. Quantification of mRNA expression via RT-qPCR Total RNA was isolated using TRIzol reagent (Invitrogen) from pellets of cells, and the quality and concentration of RNA evaluated spectrophotometrically. To produce cDNA, 1 µg of total RNA was converted using High-Capacity cDNA Reverse Transcription Kit from Applied Biosystems. By using the CFX Connect Real-time PCR Detection System (Bio-Rad) and gene specific primers, quantitative real-time PCR (qRT-PCR) was performed with SYBR Green chemistry (TakaRa TB green premix). Levels of expression were established for T-cell transcription factors (TBX21, GATA3, RORC, and FOXP3) and regulatory genes (P53, C-MYC). Reactions were performed with two technical replicates. Relative gene expression was measured as ΔΔCt method using GAPDH as the reference [8]. Flow cytometry for histone modifications and protein markers Flow cytometry analysis was performed for lymphocytes after treatment with Trichostatin A (TSA) to study the intracellular histone modifications, and the expression of Tet regulatory proteins. Cells were PBS washed before staining with primary antibodies recognizing H3K14Ac, H3K4me3, and H3K27me3 modification of the histone H3, as well as antibodies for HDAC1, c-Myc, and p53 as regulatory proteins. After incubation with primary antibodies, the cells were incubated with the secondary antibodies conjugated to the fluorescence. Post-staining acquisition was on a flow cytometer (BD FACS Melody) with appropriate laser and filter settings. By studying these markers, we could quantify alteration in levels of histone modifications and expression of regulatory proteins in response to epigenetic treatment with TSA [13]. DNA methylation analysis (qRT-PCR) DNA was extracted from PBMCs using the Quick-DNA Miniprep Plus Kit (Zymo Research), and 1 μg of the extracted DNA was further treated with bisulfite using the EZ DNA Methylation-Gold™ Kit (Zymo Research) as per manufacturer instructions. This process grounds unmethylated cytosines (which are transformed to uracil), from the methylated cytosines (left unchanged during conversion). Specific primers were generated for the qRT-PCR, via TB Green Premix Ex Taq, from TakaRa Bio, for easy analysis of CpG-rich promoters in immune-regulatory genes TBX21 and IFNG, run in the CFX Connect Real-Time PCR System (Bio-Rad). Conventional thermodynamic cycling conditions were used for amplification. To establish methylation status, we used differences in Ct values of the target methylation-specific primers compared to the reference primers. The quantitative analyses of methylation were obtained using the ΔCt method for every target locus [14]. m6A RNA methylation assay Global N6-methyladenosine (m6A) quantification in total RNA was done using the EpiQuik™ m6A RNA Methylation Quantification Kit (Colorimetric, EpigenTek), following manufacturer’s procedures. The samples’ RNA was bound evenly to the assay strip wells using the RNA High Binding Solution (BS) supplied by kit. After the RNA had stuck to the wells, an m6A specific capture antibody was introduced, followed by a detection antibody. Signal development improved by adding enhancer solution (ES) library of the kit into the procedure. After developing the color reaction one measured absorbance at the 450 nm with the aid of a microplate spectrophotometer. The m6A calculated was migrated based on the samples OD reading as compared to those produced from standard curve [15]. R-loop analysis via RDIP-qPCR Through RNA: DNA immunoprecipitation (RDIP) and q discovered on sequencing, R-loops, RNA–DNA hybrids were examined. Cells were broken by a buffer containing SDS, TE-8, and Proteinase K (Invitrogen #25,530,049), and nucleic acids were extracted with a NaCl precipitation and an ethanol cleanup. After sonication to produce fragments of ~ 400–600 bp (Covaris), samples were treated with RNase I (Ambion #AM2294) to render any remaining single-stranded RNA inaccessible. After the nucleic acids have been extracted with phenol/chloroform, and ethanol precipitated, they were resuspended in EB buffer. S9.6 antibody (ATCC #HB08730) was used to suspend the sample (3 μg/ml) overnight at 4°C before hybrid capture using M-280 sheep anti-mouse Dynabeads (Invitrogen #112.01D). IgG-incubated samples on which RNase H treatment had been performed were used as controls. Proteinase K digestion was used subsequently as a method to elute hybrids, with a combination of phenol/chloroform and Ethachinmate (Wako #312–01791) utilized for recovering samples for purification. Measurement of P53, NOTCH1, TBX21, and GATA3 by qPCR from eluted, input DNA was done using primers. R-loop abundance was measured as the IP versus input ratio normalized to the control treated with RNase H [16]. Reduced glutathione (GSH) assay Cellular glutathione amount (GSH) was measured by using the DTNB-glutathione reductase cycle test. After application of TSA PBMCs were frosted and thawed, and then centrifuged, a supernatant extract of sample was mixed with Ellman’s reagent (DTNB) and glutathione reductase. Absorbance at 412 nm was determined by spectrophotometry to obtain measuring the yellow TNB product. The calculated GSH concentrations were determined from a standard curve and reported per unit of total protein [17]. Nitric oxide (NO) assay The nitric oxide (NO) yield was quantified by determinations of nitrite (NO₂⁻) in the culture supernatant using Griess reaction. 50 µl samples of supernatant were mixed with 50 µl of Griess reagent, and incubated at room temperature for 10 min. Nitrite concentrations were determined by measuring absorbance at 550 nm in relation to analysis against a sodium nitrite standard curve [18]. Cytotoxicity assay (LDH release) Cell-mediated cytotoxicity was determined by using an LDH release measured by means of a commercial cytotoxicity detection kit (Roche). The seeding process was done by first attaching 50 µl HT-29 colorectal carcinoma cells to a 96-well plate. Later TSA-treated immune cells were then added to co-culture with a specific effector target (E:T) ratio of 1:10. After 12 h, 50 µl of culture supernatant in every well was removed to another preloaded 96-well plate with LDH reaction mixture containing NAD + and tetrazolium salt. This plate was then kept at room temperature in the dark and incubated in 15 min. Absorbance was measured after the addition of the stop solution at 490 nm. Untreated cells and cells treated with Triton X-100 were used to establish the controls for spontaneous and spontaneous release. Percentage cytotoxicity was calculated according to the formula: [(ODsample–ODbackground)/(ODmax–ODbackground)] × 100 [19]. Statistical analysis GraphPad Prism v10.1.1 (270) was used to dispense all statistical tests. Normal distribution of data was assessed using Shapiro–Wilk test. In the case of a data that met the normality criteria, the two-way analysis of variance (ANOVA) procedure was used to test the treatment and disease condition effects and the interaction of both. A post hoc analysis was given by Tukey multiple comparison test. The data were expressed as the mean ± standard deviation (SD), and p-value < 0.05 was set as a statistically significant [8] [9]. Results TSA treatment alters cytokine secretion profile in CRC-derived lymphocytes, promoting Th1 bias, and reducing immunosuppressive cytokines To determine the effects of TSA over secretion of cytokines produced by the lymphocytes derived from CRC, culture supernatants were analyzed by ELISA (Fig. 1). Treatment with TSA induced a profound increase in secretion of the Th1-associated cytokines especially IFN-γ and IL-12 (*p < 0.05). Simultaneously, the expression of IL-4, IL-7, and IL-10 molecules associated with the activation of Th2, Th17, and Treg, respectively, was significantly downregulated (*p < 0.05). The secretion of both CCL5 and Granzyme B was significantly reduced in samples after treatment with TSA (*p < 0.05). Small increases in TNF-α and small decline in IL-17 were identified, but not at a statistically significant level. Each biological replicate demonstrated an equivalent pattern of cytokine secretion alteration.Fig. 1TSA treatment in CRC lymphocytes not only enhanced the extracellular secretions of TH1-specific cytokines (IFNg, IL-12) and tumor necrotic factor (TNF-a) but also it reduced the extracellular secretion of TH2-, TH17, Treg-specific cytokines (IL-4, IL-17, and IL-10), and pro-tumorigenic factors (CCL5, Granzyme B) TSA treatment in CRC lymphocytes not only enhanced the extracellular secretions of TH1-specific cytokines (IFNg, IL-12) and tumor necrotic factor (TNF-a) but also it reduced the extracellular secretion of TH2-, TH17, Treg-specific cytokines (IL-4, IL-17, and IL-10), and pro-tumorigenic factors (CCL5, Granzyme B) TSA-induced transcriptional reprogramming enhances Th1-associated gene expression while suppressing immunosuppressive and oncogenic transcription factors in CRC lymphocytes To define the effect of TSA upon immune lineage-specific and tumor-related transcription factors, expression levels of mRNA were examined using RT-qPCR (Fig. 2). Exposure to TSA caused distinct enhancement of TBX21 expression (**p < 0.01) and increased P53 levels (*p < 0.05) in lymphocytes extracted from CRC materials. In contrast, it was found that the expression of transcription factors associated with Th2, Th17, and Treg cells such as GATA3, RORC, (**p < 0.01), and FOXP3 (*p < 0.05), respectively, was revealed marked reductions. Furthermore, TSA was revealed to profoundly reduce C-MYC expression (*p < 0.05), which was attributable to reduced pro-tumorigenic signaling activity. The pattern of transcriptional changes was the same in all tested samples.Fig. 2TSA treatment not only enhanced the expressions of TH1-specific transcription factor, TBX21, and tumor suppressor gene P53 but also diminished the expressions of TH2-, TH17-, Treg-specific transcription factors GATA3, RORC, FOXP3, and pro-tumorigenic factor, C-MYC TSA treatment not only enhanced the expressions of TH1-specific transcription factor, TBX21, and tumor suppressor gene P53 but also diminished the expressions of TH2-, TH17-, Treg-specific transcription factors GATA3, RORC, FOXP3, and pro-tumorigenic factor, C-MYC TSA modifies histone acetylation and methylation patterns, increasing transcription-permissive chromatin and modulating key regulatory proteins in CRC lymphocytes The influence of TSA on CRC lymphocytes at the epigenetic and protein expression level was analyzed using flow cytometry to quantify histone modifications and co-occurring protein expression (Fig. 3). After TSA treatment, H3K14Ac levels were increased significantly and activation-associated H3K4me3 became activated, whereas repressive H3K27me3 dropped at the same extent. TSA also significantly downregulated HDAC1 expression. After TSA administration, c-Myc as a regulatory protein was down regulated whereas p53 was upregulated. The observed modifications were reproduced across all biological replicates, describing a consistent and reproducible response to TSA-induced epigenetic changes.Fig. 3TSA treatment increased the expressions of histone acetylation (H3K14Ac) and active histone methylation (H3K4me3) markers, promoting chromatin accessibility, while reducing repressive histone methylation (H3K27me3), suggesting decreased gene silencing. TSA treatment also decreased the expression of HDAC1 confirming TSA’s inhibitory effect on histone deacetylation. TSA treatment not only suppressed the expression of oncogene, c-Myc but also it augmented the expression of tumor suppressor, p53 TSA treatment increased the expressions of histone acetylation (H3K14Ac) and active histone methylation (H3K4me3) markers, promoting chromatin accessibility, while reducing repressive histone methylation (H3K27me3), suggesting decreased gene silencing. TSA treatment also decreased the expression of HDAC1 confirming TSA’s inhibitory effect on histone deacetylation. TSA treatment not only suppressed the expression of oncogene, c-Myc but also it augmented the expression of tumor suppressor, p53 TSA reduces DNA methylation at immune gene promoters TBX21 and IFNG, facilitating epigenetic reactivation of Th1-related pathways To investigate how TSA impacts promoter-specific DNA methylation, methylation-sensitive qPCR was performed on the CpG-rich regions of the TBX21 and IFNG genes (Fig. 4). Upon TSA treatment, levels of methylation at both TBX21 and IFNG promoters were significantly reduced (*p < 0.05), and a uniform methylation level decrease was observed within all samples. Such results mean that TSA participates in enhancing gene expression through specific demethylation of DNA.Fig. 4TSA treatment decreased the frequency of R-loop (RNA:DNA hybrid) formation at the P53, NOTCH1, TBX21, and GATA3 gene loci. This reduction indicates less transcriptional interference and more stable gene expression. The decreased frequency of R-loop formation at P53 and NOTCH1 may help restore tumor suppressor activity, while the changes at TBX21 and GATA3 suggest better regulation of immune-related genes TSA treatment decreased the frequency of R-loop (RNA:DNA hybrid) formation at the P53, NOTCH1, TBX21, and GATA3 gene loci. This reduction indicates less transcriptional interference and more stable gene expression. The decreased frequency of R-loop formation at P53 and NOTCH1 may help restore tumor suppressor activity, while the changes at TBX21 and GATA3 suggest better regulation of immune-related genes TSA increases global m6A RNA methylation, suggesting modulation of post-transcriptional gene regulation in CRC-derived lymphocytes To measure epitranscriptomic changes that are induced by TSA, the m6A ratio in RNA was determined by a colorimetric method (Fig. 5). Upon exposure to TSA, the lymphocytes showed a significant increase in global m6A RNA methylations compared with untreated controls (*p < 0.05), with identical findings for CRC patient-derived and healthy lymphocytes. The hypothesis that TSA affects RNA processing and gene regulation by affecting m6A methylation is supported by the research.Fig. 5TSA treatment showed a decrease in percentage of methylation at 5′-CCGG-3′ tetranucleotide present in the CpG islands of the TBX21 and IFNG gene loci which suggested the epigenetic reprogramming, leading to a more open chromatin state and potential gene activation. This also indicated that TSA treatment might reverse CRC-associated silencing, altering immune transcriptional dynamics and influencing immune cell function TSA treatment showed a decrease in percentage of methylation at 5′-CCGG-3′ tetranucleotide present in the CpG islands of the TBX21 and IFNG gene loci which suggested the epigenetic reprogramming, leading to a more open chromatin state and potential gene activation. This also indicated that TSA treatment might reverse CRC-associated silencing, altering immune transcriptional dynamics and influencing immune cell function TSA reduces R-loop accumulation at regulatory gene loci, indicating improved transcriptional fidelity and genome stability To assess the impact of TSA on the formation of R-loops, RDIP-qPCR was used at the P53, NOTCH1, GATA3, and TBX21 gene loci (Fig. 6). TSA was found to markedly reduce the R-loop enrichment levels at the P53, NOTCH1, and GATA3 loci (***p < 0.001); however, the effect of TSA on TBX21 was milder but statistically significant (**p < 0.01). A constant reduction in R-loop levels was observed in each sample indicating TSA-regulated removal of RNA–DNA hybrids in these loci.Fig. 6TSA treatment enhanced the m6A RNA methylations in both normal subject and CRC patients, indicating potential restoration of RNA methylation balance, which may influence gene expression and immune function TSA treatment enhanced the m6A RNA methylations in both normal subject and CRC patients, indicating potential restoration of RNA methylation balance, which may influence gene expression and immune function TSA decreases intracellular glutathione levels, inducing oxidative stress in CRC-derived lymphocytes In order to determine the impact of TSA on the intracellular antioxidant capacity, the measurements of total glutathione (GSH) were performed using the colorimetric assay based on the DTNB recycling method (Fig. 7). CRC lymphocytes displayed significant decrease in GSH content after TSA treatment when compared to the untreated one (*p < 0.05). The reduction was seen in all biological replicates, which indicates that TSA exposure induces oxidative stress in CRC lymphocytes.Fig. 7TSA treatment reduces intracellular glutathione (GSH) levels in colorectal cancer cells, reflecting increased oxidative stress and depletion of antioxidant defenses. The lowered GSH content contributes to TSA-induced cytotoxicity and promotes apoptosis, highlighting the compound’s role in redox imbalance within the tumor microenvironment TSA treatment reduces intracellular glutathione (GSH) levels in colorectal cancer cells, reflecting increased oxidative stress and depletion of antioxidant defenses. The lowered GSH content contributes to TSA-induced cytotoxicity and promotes apoptosis, highlighting the compound’s role in redox imbalance within the tumor microenvironment TSA enhances nitric oxide production in CRC lymphocytes, contributing to an inflammatory and cytotoxic microenvironment To examine how TSA influences nitric oxide (NO) production, the level of nitrite in CRC lymphocyte cultures supernatants was measured via use of the Griess reaction (Fig. 8). TSA application not only stimulated the generation of NO compared to control samples (*p < 0.05) but also its enhancement was uniform throughout all the samples with minimal variation among samples.Fig. 8TSA-induced iNOS upregulation elevates nitric oxide (NO) production, enhancing oxidative and nitrosative stress in tumor cells. The increased NO levels disrupt cancer cell metabolism and promote apoptotic signaling, reinforcing TSA’s cytotoxic effects in colorectal cancer TSA-induced iNOS upregulation elevates nitric oxide (NO) production, enhancing oxidative and nitrosative stress in tumor cells. The increased NO levels disrupt cancer cell metabolism and promote apoptotic signaling, reinforcing TSA’s cytotoxic effects in colorectal cancer TSA-treated lymphocytes increased LDH release in HT-29 cells, indicating elevated cytotoxicity and membrane damage The cytotoxicity induced by TSA-treated lymphocytes against HT-29 colorectal cancer cell was determined by measuring the LDH release in culture supernatants, as a representation of damage to plasma membranes (Fig. 9). TSA treatment was characterized with a highly significant increase of LDH release, compared to controls (****p < 0.0001), which indicated a clear increase of cell toxicity. These results were present in every biological replicate of high consistency.Fig. 9TSA treatment increased lactate dehydrogenase (LDH) release and cytotoxicity in the colorectal cancer cell line HT-29. This suggests that TSA enhances cell membrane disruption and induces cell death, potentially through its epigenetic reprogramming effects. The increased LDH levels indicate TSA's potential to promote cytotoxicity and influence tumor cell viability in colorectal cancer TSA treatment increased lactate dehydrogenase (LDH) release and cytotoxicity in the colorectal cancer cell line HT-29. This suggests that TSA enhances cell membrane disruption and induces cell death, potentially through its epigenetic reprogramming effects. The increased LDH levels indicate TSA's potential to promote cytotoxicity and influence tumor cell viability in colorectal cancer Discussions This research shows that in the case of short-term, low-dosage exposure to Trichostatin A (TSA) in lymphocytes of CRC patients, epigenetic remodeling of immune-related gene networks is triggered, but without causing cytotoxicity. TSA alters transcriptional profile to a tumor-responsive and pro-inflammatory phenotype due to the coordinated chromatin regulations of histone acetylation, DNA/RNA methylation, and chromatin accessibility. These results point out to TSA serving as an immune-epigenetic modulator instead of acting as a cytotoxic substance in this case [20]. The foundation of the immunomodulatory effect of TSA is the fact that it impairs the activity of class I and II histone deacetylases (HDACs), which are normally involved in the compacted chromatin by removing the acetyl group on lysine’s histones. HDAC inhibition mediated by TSA induces the accumulation of acetylated histones, notably H3K14ac and H3K9ac that promotes chromatin decompaction and increased accessibility to transcriptional regulators. Increasing transcription-permissive H3K4me3 status and decreasing repressive mark H3K27me3 was further indicative of a global shift to open arrangements of chromatin [20]. This epigenetic change was transferred into intense immune transcriptional and functional response. TSA treatment accomplishes strong upregulation of TH1-associated cytokines, particularly IFN-y and IL-12, an inhibition of IL-4, IL-10, and IL-7 cytokines—believed to be allied with Th2, Treg, and Th17 responses. These findings indicate a dysfunctional polarization to a TH1 immune phenotype. Also, we detected a slight and steady augmentation of TNF-a, further supporting a pro-inflammatory microenvironment [21]. Transcriptional analysis revealed elevated TBX21 (T-bet) and p53 expression and a decrease in GATA3, FOXP3, and RORC, and C-MYC in the lymphocytes in TSA-treated lymphocytes. The changes are indicative of an orchestrated suppression of immunosuppressor and tumor-promoting pathways. Transcription factors, TBX21 is a master transcription factor that controls TH1 fate, whereas GATA3, FOXP3, and RORC control the fates of TH2, Treg, and TH17. The most dramatic of the changes relates to the suppression of the oncogenic driver C-MYC, which underscores the global anti-tumor transcriptomic effect of TSA. A combination of these transcriptional changes shows that TSA corrects the CRC-derived lymphocytes to a more effective immune effector state and less immunosuppressive nature [22]. Altered DNA methylation further facilitated this transcriptional reprogramming. Promoter methylation in TBX21 and IFNG was also substantially lowered in the TSA-exposed cells which means that pathways of DNA demethylation are activated. Although TSA is not specific to DNA methylation enzymes, chromatin decompaction and greater transcriptional tolerance may enhance activity of TET enzymes, especially TET2, through HDAC inhibition. TETs are involved in catalyzing bioactivity of demethylation, namely transforming 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) that facilitates further transcriptional activation of previously concerned genes. These discoveries show an epigenetic cascade in which downstream DNA methylation occurs due to upstream histone acetylation, enhancing the reactivation of immune genes [23]. Besides the chromatin-level modifications, a considerable rise in overall m6A RNA methylation was manifested when the cells received the TSA treatment. Even though TSA does not directly impair mA writers (METTL3/14) or stimulate mA erasers (FTO, ALKBH5), its more general transcriptional and epigenetic effect can change the expression of these regulators. M6A methylation is a critical process in mRNA stability and translation. The enhanced m6A could lead to strengthening of the post-transcriptional process of the immune-related transcripts which would include transcripts like IFNG and IL-12B make up their continued expression and encode effector proteins [24]. There was also diminishment in the R-loop accumulation of immunologically relevant sites, specifically GATA3, NOTCH1, and P53 due to TSA treatment. R-loops are three stranded nucleic acids with RNA:DNA hybrids structures that accompany RNA transcription and are recognized to be related to genomic instability, or chromosomal disruption, and activities of RNA interference. This chromatin relaxation caused by TSA can enhance the efficiency of RNA polymerase II elongation, thus inhibiting R-loop formation. Indicatively, slight but important decrease in R-loop levels was also seen on the TBX21 locus indicating that TSA may assist in maintaining the transcriptional fidelity at the immune effector locations [25]. In addition to effects on the epigenome and transcriptome, TSA affected major facets of metabolism and effector cell functionality of immune cells. The treatment of lymphocytes with TSA resulted in a considerable reduction of intracellular glutathione (GSH) levels, which is the indicator of a rise of oxidative stress. Such redox imbalance can potentially lead to immune activation through the reactive oxygen species (ROS) signaling. In parallel, we found a high production of nitric oxide (NO), which further supports the inflammatory and cytotoxic nature of TSA-exposed lymphocytes [26]. Functionally, these immune and metabolic reprogramming phenomena were converted into the increased activity of cytotoxicity. Lymphocytes treated with TSA subsequently excreted lactate dehydrogenase (LDH) at a dramatically higher rate when co-cultured with HT-29 colorectal cancer cells, which was an indication of increased tumor-directed membrane lysis. This indicates that TSA primes lymphocytes on more than merely a transcriptional and epigenetic level, but also increases their functional capacity to kill tumor cells directly [27]. One of the most significant findings was the up regulation of MHC class II-associated genes. The molecules play a vital role in presenting an antigen to CD4 + T cells, and it is often suppressed in colorectal cancer. The TSA-dependent rescue of MHC expression can boost the cancer immunogenicity through raising the antigen display manifested by boosting lymphocyte recruitment and the activation of T cells. Notably, although this induced immune activation, TSA did not increase exhaustion markers, like PD-1 or LAG-3, in a significant way, indicating a physiologically functioning immune response as opposed to uncontrolled hyperstimulation. This uniqueness predisposes TSA as future combiner agent with immune checkpoint inhibitors, which cannot operate without functional effector T cells to respond optimally to the therapy [28]. Mechanistically, TSA coordinated several epigenomic strategies, such as histone acetylation, DNA hypomethylation, RNA 5-methylation, and control of R-loops, into a unified transcriptional program. In contrast to mere activation of immune cells in a binary way, TSA reshapes the underlying epigenetic landscape, thereby making lymphocytes much more sensitive and effective central guardians of the tumor microenvironment. These results are consistent with an emerging concept of transcriptional training in immune epigenetics, which posits that under the influence of short-term exposure to epigenetic modifiers functional, long-lasting reprogramming can be initiated in immune cells [20]. However, there are various limitations that will have to be overcome to promote translational value. Our results are based on short-term in vitro treatment of peripheral lymphocytes that lacks the spatial and cellular complexity of in vivo tumor-immune interactions. The epigenetic effects that are brought about by TSA are not well resolved especially in terms of their long-term stability including their survival after treatment. Further, we were unable to characterize lymphocyte subsets (e.g., CD4 + T, cytotoxic CD8 + T, Tregs, NK), restricting what we could learn about lineage-specific responses that can have opposite effects on tumor control and immunosuppression [29]. Future studies ought to examine organoid-based immune co-cultures, patient-derived xenotransplants, and single-cell epigenomic profiling to analyze the fine-scale impacts of TSA on different immune lineage cells and various tissues. Moreover, following epigenetic memory, chromatin stability on extended regimens, and transcript remodeling via m6A in the face of combinatorial regimens, such as immune checkpoint inhibitors, would allow establishing whether TSA should be investigated as an enhancement or synergist of first-line immunotherapies. Last, we propose that histone acetylation profiles or R-loop signatures may serve as early biomarkers of immune reactivation, offering precision tools for tailoring epigenetic immunotherapy in colorectal cancer [30]. Conclusion The present research supports early information of the efficacy of low-dose Trichostatin A (TSA) to regulate the behavior of patient-derived immune cells in colorectal cancer (CRC) by altering epigenetic and transcriptional signs in a coordinated method. TSA led to histone acetylation, DNA and RNA methylation changes, and exacerbated R-loop levels, altogether pointing at chromatin remodeling in a direction toward pro-inflammatory gene expression. Such molecular changes were associated with augmented expression of immune-related transcription factors (e.g., TBX21, TP53), reduced expression of regulatory markers (e.g., FOXP3, GATA3) and functional consequences in terms of augmented cytokine release, augmented cytotoxicity, and redox imbalance in CRC-derived lymphocytes. Although these results affirm the possible role of TSA in epigenetically programming immune cells, these findings are constrained to experimental data on short-term in vitro studies. It is important to consider that the dual immune-epigenetic modulation described here should be considered as a working hypothesis that needs to be substantiated using more physiologically relevant models. Further in vivo analyses and clinical evaluations are required to ascertain TSA potential as a low-toxicity companion in CRC immunotherapy as well as a part of wider precision epigenetic approaches. The study adds to the amount of evidence pointing out the connection between epigenetic therapy and immune reactivation and to the potential of TSA being used as an integrative cancer immunomodulatory agent.